AN2 Therapeutics (ANTX) reported second-quarter 2026 financial results and updates across its boron chemistry pipeline, including planned and ongoing Phase 2 programs in polycythemia vera, M. abscessus lung disease and chronic Chagas disease.
The company posted a second-quarter net loss of $8.2 million, compared with $6.5 million in the same period of 2025. AN2 had $79.9 million in cash, cash equivalents and investments as of June 30, 2026, and said its current operating plan funds operations into 2029.
- Q2 R&D expenses were $6.0 million, up from $3.2 million a year earlier.
- Q2 G&A expenses were $2.9 million, down from $4.0 million a year earlier.
- Net loss per share was $0.18, compared with $0.21 in the second quarter of 2025.
- Polycythemia vera Phase 2 enrollment is anticipated to begin in the fourth quarter of 2026 after an expected third-quarter IND filing.
- M. abscessus lung disease enrollment is ongoing in an 84-patient Phase 2 investigator-initiated trial, with topline results anticipated in late 2027, subject to enrollment progress.
- Chagas disease Phase 2 proof-of-concept study initiation is expected in late 2026 following positive non-human primate efficacy data and Phase 1 safety and pharmacokinetic results.
$ANTX Insider Trading Activity
$ANTX insiders have traded $ANTX stock on the open market 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $ANTX stock by insiders over the last 6 months:
- JOSHUA M EIZEN (See Remarks) sold 5,945 shares for an estimated $24,802
- SARAH JOANNE WILLIAMS (Principal Accounting Officer) sold 327 shares for an estimated $346
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$ANTX Hedge Fund Activity
We have seen 41 institutional investors add shares of $ANTX stock to their portfolio, and 16 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- COMMODORE CAPITAL LP added 2,333,713 shares (+inf%) to their portfolio in Q1 2026, for an estimated $7,981,298
- MILLENNIUM MANAGEMENT LLC added 2,126,819 shares (+2222.8%) to their portfolio in Q1 2026, for an estimated $7,273,720
- SPRUCE STREET CAPITAL LP added 1,661,073 shares (+inf%) to their portfolio in Q1 2026, for an estimated $5,680,869
- BLACKROCK, INC. added 1,346,726 shares (+422.5%) to their portfolio in Q2 2026, for an estimated $6,518,153
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,000,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $3,420,000
- WOODLINE PARTNERS LP added 847,700 shares (+580.7%) to their portfolio in Q1 2026, for an estimated $2,899,134
- BOXER CAPITAL MANAGEMENT, LLC added 749,035 shares (+inf%) to their portfolio in Q1 2026, for an estimated $2,561,699
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
